Combination treatment of Sofosbuvir plus Daclatasvir for 12 weeks in HCV Genotype 3-Infected Bangladeshi patients: Achievment of a Sustained Virological Response

Background: Hepatitis C virus (HCV) is a major cause of chronic liver disease affecting close to 170 million people worldwide. All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. The combination of sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir, a first-in-class NS5A replication complex inhibitor, demonstrate that it is one of the most promising antiviral therapies. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (A nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 3. The aim of the study is to evaluate the efficacy and treatment response of Sofosbuvir plus Daclatasvir in HCV patients with genotype 3. Materials & Methods: A total 24 patients with genotype 3 were included in this study. Patients received tab sofosbuvir 400 mg plus tab daclatasvir 60mg daily for 12 weeks. Outcome was assessed at the end of 4 weeks (RVR), 12 weeks (EVR) and 24 weeks (SVR).Results: Twenty four patients were recruited in this study. The study population comprised 50% male and 50% female. Among them 29.2% were between 41-50 ages and 25% were between 31-40 ages. 37.5% patients complaints for loss of appetite. 79.2% were genotype 3b and 20.8% were genotype 3a. All patients received sofosbuvir (400 mg) and daclatasvir (60 mg) for 12 weeks. SVR12 100% were achieved in all of them.Conclusion: All patients with genotype 3 achieved SVR12 100% after the completion of therapy with sofosbuvir and daclatasvir. The combination of sofosbuvir and an NS5A inhibitor for 12 weeks appears to be a very good further treatment option in patients with whatever the stage of HCV.